`
` CENTER FOR DRUG EVALUATION AND
`RESEARCH
`RESEARCH
`
`
`
`
`
`APPLICATION NUMBER:
`APPLICA TI0N NUMBER:
`22-288
`
`
`LABELING
`
`LABELING
`
`
`
`
`
`22-288
`
`
`
`
`
`NDA 22-288
`Page 4
`
`Container Labels (1 mL, and 2.5 mL samples, 2.5 ml and 5 mL trade)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`NDA 22-288
`Page 5
`
`Carton Labels (1 mL, and 2.5 mL samples, 2.5 ml and 5 mL trade)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`04191 (uoiinios oiwicuiudo
`ateiisoq ounseioiloq)
`
`mil/\JE/dilgh
`
`
`Each inL Contains:
`NBC 51425-00175
`
`Active: bepotastine heSilate
`i5 mg (eouniaient to in 1 mg
`oepotastine].
`
`Preservatiue:
`HBEPREVET”
`oenzalkdnium ohioride
`0.005%
`liiactiires: monohasic
`(bepotastine besilate
`
`sodium phosphate dihydrate,
`sodium chioride, sodium
`ophthalmic solution) 1.5%
`hydrUXide to adjust pH, and
`
`Slerilo ID InL
`water for injection, USP.
`Hx only
`
`5 mL and 2.5 mL trade will look
`
`the same as this carton.
`
`
`
`NEIC 7425-0fl7v75
`
`
`
`HBEPR VE "'
`(bepotastine be ilate
`ophthalmic solution)
`%
`
`Sterile 1!] mL
`onnly
`
`\
`
`This product is steiiie when
`manufactured and shouid be
`dispensed in the originai
`unopened container instruct
`patient on precautions to
`avoid contamination
`
`Foi topical application
`in the eye.
`
`Usual dosage:
`instili one drop into the
`affected eyets] twme a day
`See accompanying
`prescribing information.
`Store at lE°—25“C (ET—770:]
`
`
`
`
`
`
`
`NDA 22-288
`NDA 22—288
`Page 6
`Page 6
`
`
`1'" [ll a”1315
`
`'\
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Manufactured for:
`
`
`ISTA Pharmaceuticals? inc.
`
`Irvine, CA 92018
`
`By:
`
`
`Eausch ELornlJ Incorporated
`
`Tampa, FL 3363?
`
`
`
`Under license from:
`F-\
`
`
`
`Seniu Pharmaceuticai Co, Ltd
`
`
`Osaka. Japan 541-0046
`
`| Sill
`
`
`
`
`9149501
`JASZ'iOS
`
`
`
`67425007756
`
`N 3
`
`
`
`/=\
`S
`I A emimmumix '
`
`Lot
`
`Exp
`
`
`
`
`
`
`
`7
`
`
`
`HIGHLIGHTS OF PRESCRIBING
`INFORMATION
`These highlights do not include all the
`information needed to use Bepreve™
`(bepotastine besilate ophthalmic solution)
`1.5% safely and effectively.
`See full prescribing information for
`Bepreve™.
`
`BEPREVE™
`(bepotastine besilate ophthalmic solution) 1.5%
`Initial U.S. Approval: 2009
`
`------------INDICATIONS AND USAGE---------
`Bepreve™ is a histamine H1 receptor antagonist
`indicated for the treatment of itching associated
`with allergic conjunctivitis. (1)
`
`--------DOSAGE AND ADMINISTRATION----
`Instill one drop into the affected eye(s) twice a
`day. (BID). (2)
`
`-------DOSAGE FORMS AND STRENGTHS--
`Solution containing bepotastine besilate, 1.5%.
`(3)
`
`
`
`-----------WARNINGS AND PRECAUTIONS-------
`• To minimize the risk of contamination, do not
`touch dropper tip to any surface. Keep bottle
`tightly closed when not in use. (5.1)
`• Bepreve™ should not be used to treat contact
`lens-related irritation. (5.2)
`• Remove contact lenses prior to instillation of
`Bepreve™. (5.2)
`
`
`-------------------ADVERSE REACTIONS------------
`The most common adverse reaction occurring in
`approximately 25% of patients was a mild taste
`following instillation. Other adverse reactions which
`occurred in 2-5% of subjects were eye irritation,
`headache, and nasopharyngitis. (6)
`
`To report SUSPECTED ADVERSE REACTIONS,
`contact ISTA Pharmaceuticals, Inc. at 1-877-788-2020,
`or FDA at 1-800-FDA-1088 or
`www.fda.gov/medwatch.
`
`See 17 for PATIENT COUNSELING
`INFORMATION
`
`Revised: 08/2009
`
`
`_____________________________________________________________________________________________
`11
`DESCRIPTION
`FULL PRESCRIBING INFORMATION:
`12
`CLINICAL PHARMACOLOGY
`CONTENTS*
`12.1 Mechanism of Action
`1
`INDICATIONS AND USAGE
`Pharmacokinetics
`12.3
`2
`DOSAGE AND ADMINISTRATION
`13
`NONCLINICAL TOXICOLOGY
`3
`DOSAGE FORMS AND STRENGTHS
`13.1
`Carcinogenesis, Mutagenesis and Impairment
`4
`CONTRAINDICATIONS
`of Fertility
`5 WARNINGS AND PRECAUTIONS
`
`5.1 Contamination of Tip and Solution
`CLINICAL STUDIES
`
`5.2 Contact Lens Use
`HOW SUPPLIED/STORAGE AND
`
`5.3 Topical Ophthalmic Use Only
`HANDLING
`PATIENT COUNSELING INFORMATION
`6
`ADVERSE REACTIONS
`Topical Ophthalmic Use Only
`8
`USE IN SPECIFIC POPULATIONS
`Sterility of Dropper Tip
`
`8.1
`Pregnancy
`Concomitant Use of Contact Lenses
`
`8.3 Nursing Mothers
`
`8.4
`Pediatric Use
`
`8.5 Geriatric Use
`
`17
`17.1
`17.2
`17.3
`
`*Sections or subsections omitted from the full
`prescribing information are not listed
`____________________________________________________________________________________________
`
`14
`16
`
`.
`
`
`
`
`
`
`
`
`oral doses up to 200 mg/kg/day (representing a
`systemic concentration approximately 3300 times
`that anticipated for topical ocular use in humans),
`but did show some potential for causing skeletal
`abnormalities at 1000 mg/kg/day. There were no
`teratogenic effects seen in rabbits at oral does up
`to 500 mg/kg/day given during organogenesis and
`fetal development (>13,000 times the dose in
`humans on a mg/kg basis). Evidence of infertility
`was seen in rats given oral bepotastine besilate
`1000 mg/kg/day, however, no evidence of
`infertility was observed in rats given
`200 mg/kg/day (approximately 3300 times the
`topical ocular use in humans). The concentration
`of radiolabeled bepotastine besilate was similar in
`fetal liver and maternal blood plasma following a
`single 3 mg/kg oral dose. The concentration in
`other fetal tissues was one-third to one-tenth the
`concentration in maternal blood plasma.
`
`An increase in stillborns and decreased growth
`and development were observed in pups born from
`rats given oral doses of 1000 mg/kg/day during
`perinatal and lactation periods. There were no
`observed effects in rats treated with 100
`mg/kg/day.
`
`There are no adequate and well-controlled studies
`of bepotastine besilate in pregnant women.
`Because animal reproduction studies are not
`always predictive of human response, Bepreve™
`(bepotastine besilate ophthalmic solution) 1.5%
`should be used during pregnancy only if the
`potential benefit justifies the potential risk to the
`fetus.
`
`
`8.3 Nursing Mothers
`Following a single 3 mg/kg oral dose of radio-
`labeled bepotastine besilate to nursing rats 11
`days after delivery, the maximum concentration
`of radioactivity in milk was 0.40 µg eq/mL 1
`hour after administration; at 48 hours after
`administration the concentration was below
`detection limits. The milk concentration was
`higher than the maternal blood plasma
`concentration at each time of measurement.
`
`It is not known if bepotastine besilate is excreted
`in human milk. Caution should be exercised
`when Bepreve™ (bepotastine besilate
`ophthalmic solution) 1.5% is administered to a
`nursing woman.
`
`
`8.4 Pediatric Use
`Safety and efficacy of Bepreve (bepotastine
`besilate ophthalmic solution) 1.5% have not
`
`8
`
`
`
`FULL PRESCRIBING INFORMATION
`
` 1
`
`
`
`INDICATIONS AND USAGE
`Bepreve™ (bepotastine besilate ophthalmic
`solution) 1.5% is a histamine H1 receptor
`antagonist indicated for the treatment of itching
`associated with signs and symptoms of allergic
`conjunctivitis.
`
`2 DOSAGE AND ADMINISTRATION
`Instill one drop of Bepreve™ into the affected
`eye(s) twice a day (BID).
`
`3 DOSAGE FORMS AND STRENGTHS
`Topical ophthalmic solution containing
`bepotastine besilate 1.5%
`
`4 CONTRAINDICATIONS
`None.
`
`5 WARNINGS AND PRECAUTIONS
`5.1 Contamination of Tip and Solution
`To minimize contaminating the dropper tip and
`solution, care should be taken not to touch the
`eyelids or surrounding areas with the dropper tip
`of the bottle. Keep bottle tightly closed when
`not in use.
`
`
`5.2 Contact Lens Use
`Patients should be advised not to wear a contact
`lens if their eye is red. Bepreve™ should not be
`used to treat contact lens-related irritation.
`Bepreve™ should not be instilled while wearing
`contact lenses. Remove contact lenses prior to
`instillation of Bepreve™. The preservative in
`Bepreve™, benzalkonium chloride, may be
`absorbed by soft contact lenses. Lenses may be
`reinserted after 10 minutes following
`administration of Bepreve™.
`
`
`5.3 Topical Ophthalmic Use Only
`Bepreve™ is for topical ophthalmic use only.
`
`
`6 ADVERSE REACTIONS
`The most common reported adverse reaction
`occurring in approximately 25% of subjects was
`a mild taste following instillation. Other adverse
`reactions occurring in 2-5% of subjects were eye
`irritation, headache, and nasopharyngitis.
`
`
`USE IN SPECIFIC POPULATIONS
`8
`8.1 Pregnancy
`Pregnancy Category C: Teratogenicity studies
`have been performed in animals. Bepotastine
`besilate was not found to be teratogenic in rats
`during organogenesis and fetal development at
`
`
`
`
`
`
`
`9
`
`
`
`been established in pediatric patients under 2
`years of age. Efficacy in pediatric patients
`under 10 years of age was extrapolated from
`clinical trials conducted in pediatric patients
`greater than 10 years of age and from adults.
`
`
`8.5 Geriatric Use
`No overall difference in safety or effectiveness
`has been observed between elderly and
`younger patients.
`
`11 DESCRIPTION
`Bepreve™ (bepotastine besilate ophthalmic
`solution) 1.5% is a sterile, topically
`administered drug for ophthalmic use. Each
`mL of Bepreve™ contains 15 mg bepotastine
`besilate. Bepotastine besilate is designated
`chemically as (+) -4-[[(S)-p-chloro-alpha -2-
`pyridylbenzyl]oxy]-1-piperidine butyric acid
`monobenzenesulfonate. The chemical
`structure for bepotastine besilate is:
`
`
`Bepotastine besilate is a white or pale
`yellowish crystalline powder. The molecular
`weight of bepotastine besilate is 547.06
`daltons. Bepreve™ ophthalmic solution is
`supplied as a sterile, aqueous 1.5% solution,
`with a pH of 6.8.
`
`The osmolality of Bepreve™ (bepotastine
`besilate ophthalmic solution) 1.5% is
`approximately 290 mOsm/kg.
`
`Each mL of Bepreve™ (bepotastine besilate
`ophthalmic solution) 1.5% contains:
`Active:
`Bepotastine besilate15 mg (equivalent to 10.7
`mg bepotastine)
`Preservative: benzalkonium chloride 0.005%
`Inactives: monobasic sodium phosphate
`dihydrate, sodium chloride, sodium hydroxide
`to adjust pH, and water for injection, USP.
`
`
`
`
`
`
`
`CLINICAL PHARMACOLOGY
`12
`12.1 Mechanism of Action
`Bepotastine is a topically active, direct H1-
`receptor antagonist and an inhibitor of the
`release of histamine from mast cells.
`
`
`
`
`
`
`
`
`
`12.3 Pharmacokinetics
`Absorption: The extent of systemic exposure
`to bepotastine following topical ophthalmic
`administration of bepotastine besilate 1% and
`1.5% ophthalmic solutions was evaluated in 12
`healthy adults. Following one drop of 1% or
`1.5% bepotastine besilate ophthalmic solution
`to both eyes four time daily (QID) for seven
`days, bepotastine plasma concentrations
`peaked at approximately one to two hours
`post-instillation. Maximum plasma
`concentration for the 1% and 1.5% strengths
`were 5.1 ± 2.5 ng/mL and 7.3 ± 1.9 ng/mL,
`respectively. Plasma concentration at 24 hours
`post-instillation were the below quantifiable
`limit (2ng/mL) in 11/12 subjects in the two
`dose groups.
`
`Distribution: The extent of protein binding of
`bepotastine is approximately 55% and
`independent of bepotastine concentration.
`
`
`Metabolism: In vitro metabolism studies with
`human liver microsomes demonstrated that
`bepotastine is minimally metabolized by
`CYP450 isozymes.
`In vitro studies demonstrated that bepotastine
`besilate does not inhibit the metabolism of
`various cytochrome P450 substrate via
`inhibition of CYP3A4, CYP2C9, and
`CYP2C19. The effect of bepotastine besilate
`on the metabolism of substrates of CYP1A2,
`CYP2C8, CYP2D6 was not studied.
`Bepotastine besilate has a low potential for
`drug interaction via inhibition of CYP3A4,
`CYP2C9, and CYP2C19.
`
`Excretion: The main route of elimination of
`bepotastine besilate is urinary excretion (with
`approximately 75-90% excreted unchanged in
`urine).
`
`
`13 NONCLINICAL TOXICOLOGY
`13.1 Carcinogenesis, Mutagenesis and
`Impairment of Fertility
`Long term dietary studies in mice and rats were
`conducted to evaluate the carcinogenic
`potential of bepotastine besilate. Bepotastine
`besilate did not significantly induce neoplasms
`in mice receiving a nominal dose of up to
`200 mg/kg/day for 21 months or rats receiving
`a nominal dose of up to 97 mg/kg/day for 24
`months. Theses dose levels represent systemic
`exposures approximating 350 and 200 times
`that achieved with human topical ocular use.
`The no observable adverse effect level for
`
`
`
`17.2 Sterility of Dropper Tip
`Patients should be advised to not touch dropper
`tip to any surface, as this may contaminate the
`contents.
`
`17.3 Concomitant Use of Contact Lenses
`Patients should be advised not to wear a
`contact lens if their eye is red. Patients should
`be advised that Bepreve™ should not be used
`to treat contact lens-related irritation.
`Patients should also be advised to remove
`contact lenses prior to instillation of
`Bepreve™. The preservative in Bepreve™,
`benzalkonium chloride, may be absorbed by
`soft contact lenses. Lenses may be reinserted
`after 10 minutes following administration of
`Bepreve™.
`
`
`
`©ISTA Pharmaceuticals, Inc.
`Manufactured for: ISTA Pharmaceuticals®,
`Inc.
`Irvine, CA 92618
`
`By: Bausch & Lomb Incorporated
`Tampa, FL 33637
`
`Under license from:
`Senju Pharmaceutical Co., Ltd.
`Osaka, Japan 541-004
`
` ®
`
` and ™ marks owned by ISTA
`Pharmaceuticals, Inc.
`U.S. Patents: 6,307,052; 6,780,877
`
`
`
`10
`
`
`
`bepotastine besilate based on nominal dose
`levels in carcinogenicity tests were 18.7 to 19.9
`mg/kg/day in mice and 9.6 to 9.8 mg/kg/day in
`rats (representing exposure margins of
`approximately 60 and 20 times the systemic
`exposure anticipated for human topical use).
`
`There was no evidence of genotoxicity in the
`Ames test, in CHO cells (chromosome
`aberrations), in mouse hepatocytes
`(unscheduled DNA synthesis), or in the mouse
`micronucleus test.
`
`When oral bepotastine was administered to
`male and female rats at doses up to 1,000
`mg/kg/day, there was a slight reduction in
`fertility index and surviving fetuses. Infertility
`was not seen in rats given 200 mg/kg/day oral
`bepotastine besilate (approximately 3300 times
`the systemic concentration anticipated for
`topical ocular use in humans).
`
`
`
`14
`
`CLINICAL STUDIES
`Clinical efficacy was evaluated in 2
`conjunctival allergen challenge (CAC) studies
`(237 patients). Bepreve (bepotastine besilate
`ophthalmic solution) 1.5% was more effective
`than its vehicle for relieving ocular itching
`induced by an ocular allergen challenge, both
`at CAC 15 minutes post-dosing and a CAC 8
`hours post dosing of Bepreve.
`
`The safety of Bepreve™ was evaluated in a
`randomized clinical study of 861 subjects over
`a period of 6 weeks.
`
`16 HOW SUPPLIED/STORAGE AND
`HANDLING
`Bepreve™ (bepotastine besilate ophthalmic
`solution) 1.5% is supplied in a white low
`density polyethylene plastic squeeze bottle
`with a white controlled dropper tip and a white
`polypropylene cap in the following sizes:
`
`2.5 mL (NDC 67425-007-12)
`5 mL (NDC 67425-007-50)
`10 mL (NDC 67425-007-75)
`
`STORAGE
`Store at 15º – 25ºC (59º – 77ºF).
`
`PATIENT COUNSELING INFORMATION
`17
`17.1 Topical Ophthalmic Use Only
`
`For topical ophthalmic administration only.
`
`
`
`
`
`
`
`
`
`Application
`Type/Number
`--------------------
`NDA-22288
`
`Submission
`Type/Number
`--------------------
`ORIG-1
`
`Submitter Name
`
`Product Name
`
`--------------------
`ISTA
`PHARMACEUTICA
`LS
`
`------------------------------------------
`BEPOTASTINE BESILATE
`OPHTHALMIC SOLUTION
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`WILEY A CHAMBERS
`09/08/2009
`
`EDWARD M COX
`09/08/2009
`
`